People · Operator
Named in public records as an officer, director or promoter · active 2021–2026 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Vaxess Technologies, Inc. | — | Biotechnology | Series C | $138.2M | $269.9M | 2021 |
| Iliad Biotechnologies, Inc. | — | Biotechnology | Series D+ | $115.5M | $747.3M | 2026 |
| Curevo, Inc. | — | Pharmaceuticals | Series C | $110.0M | $293.0M | 2021 |
Mario Barro at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Mario Barro on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Ann DeWitt | 1 | 10 |
| Peter Kolchinsky | 1 | 8 |
| Aaron Sandoski | 1 | 7 |
| Avi Naider | 1 | 6 |
| Rachel Sha | 1 | 4 |
| Michael Schrader | 1 | 3 |
| Eric Edidin | 1 | 3 |
| Purnanand Sarma | 1 | 3 |
| Fenel Eloi | 1 | 3 |
| James Connolly | 1 | 3 |
| Mark Tracy | 1 | 3 |
| Moncef Slaoui | 1 | 3 |
| Tal Zaks | 1 | 3 |
| KEITH RUBIN | 1 | 2 |
| Charles Petty | 1 | 2 |
| Livio Valenti | 1 | 2 |
| Johannes Fruehauf | 1 | 2 |
| Giovanni Mariggi | 1 | 2 |
| George Simeon | 1 | 1 |
| Jae Uk Jeong | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.